1. MO1-19-2 Retrospective comparison between Nivolumab and Irinotecan for advanced gastric cancer.
- Author
-
Ishii, Takahiro, Kawazoe, Akihito, Nakamura, Yoshiaki, Sasaki, Akinori, Mishima, Saori, Kotani, Daisuke, Kuboki, Yasutoshi, Taniguchi, Hiroya, Kojima, Takashi, Doi, Toshihiko, Yoshino, Takayuki, Kuwata, Takeshi, and Shitara, Kohei
- Subjects
- *
STOMACH cancer , *TREATMENT effectiveness , *BRACHIAL plexus , *TAXANES , *BIOMARKERS - Abstract
Background Nivolumab showed a survival benefit compared to placebo in patients (pts) with advanced gastric cancer (AGC) after two or more previous lines of chemotherapy. However, it remains unclear whether to use nivolumab or irinotecan in AGC pts as a third- or later-line treatment. Meanwhile, ECOG PS or molecular characteristics are associated with outcomes after PD1 blockade for AGC (Shitara K, et al, Lancet 2018; Mishima S, et al, JITC 2019). Methods AGC Pts treated with nivolumab or irinotecan after fluoropyrimidine based regimens and taxanes from May 2016 to November 2018 were analyzed. Subgroup analysis was conducted according to ECOG PS or other clinicopathological characteristics. Results Total 128 pts (58 in the nivolumab group and 70 in the irinotecan group) were included in this study. The median PFS were both 1.9 months (HR 0.85; 95% CI, 0.58-1.27). Nivolumab showed a longer PFS than that of irinotecan in pts with ECOG PS of 0 (N = 66), with median PFS of 3.1 vs. 2.0 months (HR, 0.53; 95% CI, 0.30-0.94), while irinotecan showed a trend of longer PFS in pts with ECOG PS of 1 or more (N = 62; median 1.1 vs. 1.8 months; HR 1.51; 95% CI, 0.87-2.63; p for interaction = 0.009). Interaction between treatment effect and ECOG PS was consistent if it was limited to microsatellite stable AGC. Conclusions ECOG PS was associated with outcomes after nivolumab or irinotecan in AGC pts as a third- or later-line, which warrants further evaluation in a larger cohort. Biomarker analysis will be presented at the meeting. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF